论文部分内容阅读
作者以静脉注射溴化脱氧尿嘧啶(Brdu)后,取外周血、骨髓抽取液和骨髓活检。经抗Brdu单克隆抗体(RPMB Ⅰ)和荧光素(FITC)处理后,在荧光显微镜下观察体内S期细胞的Brdu结合情况,以确定髓性白血病的增殖特点,共观察了14例急性非淋巴细胞白血病和1例慢粒急粒变。将15例病人体内、体外Brdu掺合情况进行比较,可清楚地观察到每一个病人的两组骨髓抽取液S期细胞百分率比较接近。不仅两组的平均值相似(7.3/7.8%),而且每个病人的两个数值也大体相同。因此,体内和体外标记条件的差异不会引起骨髓抽取液中标记细胞百分率的不同。
After intravenous bromodeoxyuridine (Brdu), the authors took peripheral blood, bone marrow extract and bone marrow biopsy. The anti-Brdu monoclonal antibody (RPMB Ⅰ) and fluorescein (FITC) treatment, under the fluorescent microscope observed S phase cells in the Brdu binding to determine the proliferation of myeloid leukemia characteristics were observed in 14 cases of acute non-lymph Cellular leukemia and 1 case of CML. Comparison of Brdu incorporation in vitro and in vivo in 15 patients clearly shows that the percentage of S phase cells in two groups of bone marrow aspirates in each patient is relatively close. Not only did the mean values of the two groups be similar (7.3 / 7.8%), but the two values for each patient were also roughly the same. Therefore, differences in labeling conditions in vivo and in vitro do not cause differences in the percentage of labeled cells in bone marrow aspirate.